Board Meeting Details

The Board Meeting commenced at 02:00 P.M. (IST) and concluded at 06:05 P.M. (IST) on November 4, 2026.

Key Approvals and Notings

1. Financial Results Approval: Pursuant to Regulation 33 of SEBI Listing Regulations, the Board approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026, along with Limited Review Reports with an unmodified opinion issued by the Statutory Auditors.

2. ESOP Grant: Pursuant to the approval of the Nomination & Remuneration Committee, the Board noted the grant of fresh 49,712 Employee Stock Options under the existing "Entero Employee Stock Option Plan 2023".

Financial Results - Standalone (Amount in Millions, except per share data)

Quarter Ended September 30, 2026
  • Revenue from operations: ₹1,141.57
  • Other income: ₹220.82
  • Total income: ₹1,366.53
  • Total expenses: ₹1,123.34
  • Profit before tax: ₹243.19
  • Tax expense: ₹51.75
  • Profit for the period: ₹191.44
  • Basic EPS: ₹4.40
  • Diluted EPS: ₹4.39
Half Year Ended September 30, 2026
  • Revenue from operations: ₹1,978.37
  • Other income: ₹452.27
  • Total income: ₹2,430.64
  • Total expenses: ₹2,141.40
  • Profit before tax: ₹289.24
  • Tax expense: ₹63.23
  • Profit for the period: ₹226.01
  • Basic EPS: ₹5.19
  • Diluted EPS: ₹5.18

Financial Results - Consolidated (Amount in Millions, except per share data)

Quarter Ended September 30, 2026
  • Revenue from operations: ₹20,870.75
  • Other income: ₹39.92
  • Total income: ₹20,910.67
  • Total expenses: ₹20,126.80
  • Profit before tax: ₹783.87
  • Tax expense: ₹176.45
  • Profit for the period: ₹607.42
  • Basic EPS: ₹10.47
  • Diluted EPS: ₹10.45
Half Year Ended September 30, 2026
  • Revenue from operations: ₹40,275.70
  • Other income: ₹89.99
  • Total income: ₹40,345.69
  • Total expenses: ₹38,890.62
  • Profit before tax: ₹1,455.07
  • Tax expense: ₹327.14
  • Profit for the period: ₹1,127.93
  • Basic EPS: ₹19.24
  • Diluted EPS: ₹19.20

Key Balance Sheet Highlights (Standalone)

As at September 30, 2026
  • Total assets: ₹22,297.14 million
  • Total equity: ₹17,125.11 million
  • Total liabilities: ₹5,172.03 million
  • Share capital: ₹435.23 million
  • Other equity: ₹16,649.60 million

Key Balance Sheet Highlights (Consolidated)

As at September 30, 2026
  • Total assets: ₹38,711.24 million
  • Total equity: ₹18,743.43 million
  • Total liabilities: ₹19,967.81 million
  • Share capital: ₹435.23 million
  • Other equity: ₹17,335.61 million
  • Non-controlling interests: ₹932.31 million

Subsidiary Investments During the Period

The Company subscribed to Optionally Convertible Debentures (OCDs) issued by its subsidiaries during the period ended September 30, 2026:

  • Saurashtra Medisolutions Private Limited: ₹36.250 million on May 9, 2026
  • Sai Pharma Distributors Private Limited: ₹38,000 on April 27, 2026
  • S.S. Pharma Traders Private Limited: ₹4,000 on May 22, 2026
  • Sri Parshva Pharma Distributors Private Limited: ₹62.500 on August 8, 2026

Subsequent Event

Post September 30, 2026, the Company subscribed to 15,00,000 Optionally Convertible Debentures (OCDs) issued by Chhabra Healthcare Solution Private Limited at ₹120 per OCD on November 3, 2026.

ESOP Details

During the period ended September 30, 2026:

  • The Company allotted 12,135 equity shares of ₹10 each at a premium of ₹794 per share aggregating to ₹9.76 million pursuant to exercise of employee stock options
  • The Company granted 24,800 employee stock options under Entero Employee Stock Option Plan 2023

Trading Window Closure

The trading window for dealing in securities of the Company shall open after expiry of 48 hours from the disclosure of financial results, as per the Company's Code of Fair Disclosure of Unpublished Price Sensitive Information.

Auditor's Review

The statutory auditors, M S K A & Associates LLP, have expressed an unmodified conclusion on both standalone and consolidated unaudited financial results.